{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=Fate+Therapeutics",
    "query": {
      "sponsor": "Fate Therapeutics",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 25,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=Fate+Therapeutics&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&sponsor=Fate+Therapeutics&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T06:41:02.837Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06241456",
      "title": "FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "FT825",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fate Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 351,
      "start_date": "2024-01-05",
      "completion_date": "2044-05-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-09",
      "last_synced_at": "2026-10-17T06:41:02.837Z",
      "location_count": 14,
      "location_summary": "Gilbert, Arizona • La Jolla, California • New Haven, Connecticut + 11 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06241456"
    },
    {
      "nct_id": "NCT01627314",
      "title": "The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematologic Malignancies"
      ],
      "interventions": [
        {
          "name": "ProHema-CB",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Untreated CB",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Fate Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "15 Years to 65 Years"
      },
      "enrollment_count": 62,
      "start_date": "2012-07",
      "completion_date": "2017-05",
      "has_results": false,
      "last_update_posted_date": "2021-11-30",
      "last_synced_at": "2026-10-17T06:41:02.837Z",
      "location_count": 11,
      "location_summary": "Duarte, California • Atlanta, Georgia • Maywood, Illinois + 6 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01627314"
    },
    {
      "nct_id": "NCT04551885",
      "title": "FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "FT516",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "IL-2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fate Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2020-09-07",
      "completion_date": "2023-08-11",
      "has_results": false,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-10-17T06:41:02.837Z",
      "location_count": 3,
      "location_summary": "Minneapolis, Minnesota • Hackensack, New Jersey • Houston, Texas",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04551885"
    },
    {
      "nct_id": "NCT02354443",
      "title": "A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metabolic Disorders"
      ],
      "interventions": [
        {
          "name": "ProHema-CB Transplant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Fate Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Year to 18 Years"
      },
      "enrollment_count": 1,
      "start_date": "2015-06",
      "completion_date": "2017-02",
      "has_results": true,
      "last_update_posted_date": "2018-10-10",
      "last_synced_at": "2026-10-17T06:41:02.837Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Durham, North Carolina",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02354443"
    },
    {
      "nct_id": "NCT01527838",
      "title": "Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma (NHL)",
        "Hodgkin's Disease",
        "Chronic Lymphocytic Leukemia (CLL)",
        "Acute Myelogenous Leukemia (AML)",
        "Acute Lymphoblastic Leukemia (ALL)"
      ],
      "interventions": [
        {
          "name": "Single FT1050 treated UCB unit",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Fate Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2012-01",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2016-09-12",
      "last_synced_at": "2026-10-17T06:41:02.837Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Columbus, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01527838"
    },
    {
      "nct_id": "NCT04093622",
      "title": "Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hematological Malignancy"
      ],
      "interventions": [
        {
          "name": "Genetically engineered NK cells",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Fate Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2019-10-04",
      "completion_date": "2020-04-09",
      "has_results": false,
      "last_update_posted_date": "2022-08-29",
      "last_synced_at": "2026-10-17T06:41:02.837Z",
      "location_count": 5,
      "location_summary": "Phoenix, Arizona • San Diego, California • Minneapolis, Minnesota + 2 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04093622"
    },
    {
      "nct_id": "NCT06308978",
      "title": "A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)",
        "Idiopathic Inflammatory Myositis (IIM)",
        "Systemic Sclerosis (SSc)",
        "Systemic Lupus Erythematosus (SLE)",
        "Lupus Nephritis"
      ],
      "interventions": [
        {
          "name": "FT819",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fate Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "12 Years to 70 Years"
      },
      "enrollment_count": 244,
      "start_date": "2024-03-28",
      "completion_date": "2042-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-17T06:41:02.837Z",
      "location_count": 16,
      "location_summary": "Beverly Hills, California • Fullerton, California • Irvine, California + 13 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06308978"
    },
    {
      "nct_id": "NCT04629729",
      "title": "FT819 in Subjects With B-cell Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma, B-Cell",
        "Chronic Lymphocytic Leukemia",
        "Precursor B-Cell Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "FT819",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "IL-2",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fate Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2021-07-12",
      "completion_date": "2039-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-10-17T06:41:02.837Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Davis, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04629729"
    },
    {
      "nct_id": "NCT07570862",
      "title": "A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lupus Nephritis",
        "Systemic Lupus Erythematosus",
        "SLE - Systemic Lupus Erythematosus",
        "Lupus Nephritis - WHO Class III",
        "Lupus Nephritis - WHO Class IV"
      ],
      "interventions": [
        {
          "name": "FT819",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Fate Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "12 Years to 70 Years"
      },
      "enrollment_count": 53,
      "start_date": "2026-07-27",
      "completion_date": "2030-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-17T06:41:02.837Z",
      "location_count": 12,
      "location_summary": "Beverly Hills, California • Fontana, California • Fullerton, California + 8 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fontana",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07570862"
    },
    {
      "nct_id": "NCT02743351",
      "title": "Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hematologic Malignancies",
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Myelodysplastic Syndromes",
        "Chronic Myelogenous Leukemia",
        "Acute Graft-versus-host Disease"
      ],
      "interventions": [
        {
          "name": "ProTmune",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control Arm",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Fate Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2016-12-20",
      "completion_date": "2021-11-05",
      "has_results": true,
      "last_update_posted_date": "2023-02-08",
      "last_synced_at": "2026-10-17T06:41:02.837Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Duarte, California • San Diego, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02743351"
    }
  ]
}